The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...
Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...
Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...
For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...
MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER, Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc.
Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...
Recent developments in oncology have increasingly focused on precision, non-invasive treatment modalities and structured multidisciplinary care. Within this clinical context, Dr Neeraj Dhingra, ...
Radiosurgery New York (RSNY) Demystifies Kinds of Prostate Cancer for Enhanced Patient Awareness NEW YORK, NY, USA, August 24, 2023/EINPresswire.com/ -- Radiosurgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results